Tissue biomarkers
Accumulation of copy number alterations and clinical progression across advanced prostate cancer
Grist E, et al. Genome Medicine. 2022
https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-022-01080-4
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial
Feng F, et al. JAMA Oncol. 2021
https://jamanetwork.com/journals/jamaoncology/fullarticle/2776225
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial
Gilson C, et al. JCO Precision Oncology. 2020
https://ascopubs.org/doi/abs/10.1200/PO.19.00388
Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
Attard G, et al. Clin Cancer Res. 2015
http://clincancerres.aacrjournals.org/content/21/7/1621.long
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Richards J, et al. Cancer Res. 2012